Skip to content

Cardiovascular function in children with heart failure with preserved ejection fraction

Cardiovascular function in children with heart failure with preserved ejection fraction - Cardiovascular function in children with heart failure with preserved ejection fraction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000010821
Enrollment
40
Registered
2013-05-29
Start date
2013-05-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction in children Control

Interventions

Transient inferior vena caval occlusion test about 10 seconds Small amount of dobutamine infusion test. 15 minutes

Sponsors

Saitama Medical Center, Saitama Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Children who are indicated for cardiac catheterization. 2) Children who have heart failure symptoms despite preserved ejection fraction (EF>50%) by echocardiography 3) HFpEF is defined as having HF signs or symptoms with LV EF greater than 50%. Clinical signs and symptoms of HF with no other identifiable cause and improvement following diuresis are: dyspnea on exertion/milk feeding, bilateral edema of the lower extremities, or hepatomegaly. Lung diseases, particularly chronic forms, were carefully screened and ruled out as non-cardiac causes of symptoms by both chest radiography and medical history. Patients presenting with HF signs or symptoms that were associated with increased pulmonary blood flow or atrio-ventricular regurgitation (more than grade II by echocardiography) were excluded. Other exclusion criteria were being within two months after surgical correction of cardiovascular lesions, univentricular circulation, hypertrophic/ restrictive cardiomyopathies, and chromosomal abnormalities. 4) Control patients: ventricular septal defect or patent ductus arteriosus (pulmonary to systemic output ratio < 1.3) 5) Written informed consent is obtained from the parents of all patients

Exclusion criteria

Exclusion criteria: Patients who cannot perform all scheduled evaluations because of their poor conditions.

Design outcomes

Primary

MeasureTime frame
Preload: LV end-diastolic area Afterload: Effective arterial elastance (Ea) Contractility: End-systolic elastance (Ees), preload recruitable stroke work Diastolic function: End-diastolic pressure area relationship, time constant of relaxation Heart rate Ventricular-vascular coupling: Ees/Ea Dobutamine induced changes of above indices.

Countries

Japan

Contacts

Public ContactSatoshi Masutani

Saitama Medical Center, Saitama Medical School Pediatrics

smstn@ka2.so-net.ne.jp049-228-3550

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026